Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treatment of cancer

A conjugate, cell therapy technology, applied in biochemical equipment and methods, chemical instruments and methods, for targeting specific cell fusion, etc.

Pending Publication Date: 2018-09-28
ALETA BIOTHERAPEUTICS INC
View PDF18 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The use of such CAR T cells involves recognizing antigens to which CAR T cells on tumor cells can bind, but tumor heterogeneity can make antigen recognition challenging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treatment of cancer
  • Compositions and methods for treatment of cancer
  • Compositions and methods for treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0391] Example 1. Construction and expression of antibody-CD19 fusion protein

[0392] The fusion protein containing CD19 and full-length antibody or scFv uses anti-EGFR monoclonal antibody palimumab, humanized anti-c-MET monoclonal antibody LY2875358 (emibetuzumab) or anti-HER2 monoclonal antibody trastuzumab To produce. The C-terminal lacks 13 amino acids and includes two C2-type Ig domains of CD19 ("CD19-D1+D2", which contains the non-coding sequence in the CD19 gene and the coding sequence of exons 1-4) of CD19 The extracellular domain is fused to the full-length antibody in various orientations, such as Figure 13 Exemplarily depicted in. In some constructs, only CD19 domain 1 ("CD19-D1") or domain 2 ("CD19-D2") is used for the fusion protein. In some constructs, the full-length extracellular domain of CD19 ("CD19-ECD"; SEQ ID NO: 112) is used.

[0393] Palimumab-CD19 fusion protein is produced in 293T cells by expressing a vector containing a nucleic acid encoding Palimuma...

example 2

[0400] Example 2. Antibody-CD19 fusion protein is recognized by anti-CD19 antibody

[0401] Various methods were used to determine the ability of the anti-CD19 antibody (FMC63) to bind to the various antibody-CD19 fusion proteins described in Example 1 to demonstrate specific binding.

[0402] Figure 17A to 17D The binding of the Palimumab-CD19 fusion protein described in Example 1 to FMC63 is depicted. The ELISA plate (Pierce) was coated with 1 μg / ml FMC63 anti-human CD19 antibody (Millipore) overnight at 4°C. The plate was blocked with 0.3% NF milk powder in TBS at room temperature for 1 hour. The cell culture supernatant was directly added to the wells in the ELISA buffer, and then serially diluted at a dilution of 1:3 to 1:2187. The ELISA plate was gently washed three times with TBST (50 mM Tris, 150 mM NaCl, 0.05% Tween 20) ELISA buffer, and then peroxidase-conjugated polyclonal anti-human IgG was added to detect bound human antibodies. In this assay format, human antibodi...

example 3

[0406] Example 3. LY2875358-CD19 fusion protein binds to A549 cancer cells and binds to anti-CD19 antibody

[0407] LY2875358-CD19 fusion protein (the construct “37+10” described in Example 1) was tested for binding to A549 cancer cells and FMC63 (also called “FACS” or “flow cytometry”) by fluorescence activated cell sorting ( Anti-CD19 antibody) ability. A549 cells express c-MET, a cancer cell-associated protein specifically recognized by LY2875358. LY2875358 HC (SEQ ID NO: 7) and LY2875358LC (SEQ ID NO: 10) were expressed in 293T cells, and the cell culture supernatant was incubated with A549 cells. After 30 minutes of incubation on ice, the cells were washed with FACS buffer (PBS with 1% BSA and 0.1% sodium azide). The bound antibody is then detected by incubating the cells with an anti-human IgG-fluorescein isothiocyanate (FITC) conjugate, which emits a fluorescent signal when activated by a specific laser in the flow cytometer . The resulting FACS signal can be regarded ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compositions, e.g., compositions comprising cellular therapeutics and / or protein therapeutics, and methods of using such compositions for treating cancer are described.

Description

[0001] Cross references to related applications [0002] This application requires priority for each of the U.S. Provisional Patent Application No. 62 / 249,144 filed on October 30, 2015; 62 / 331,010 filed on May 3, 2016; and 62 / 396,783 filed on September 19, 2016 Right, the entire contents of each of these patents are incorporated herein by reference. Background technique [0003] Adoptive cell therapy (ACT) is a treatment method in which cells are removed from a donor, cultured and / or manipulated in vitro, and then administered to the patient to treat the disease. Many cell types have been used in ACT in an attempt to treat several types of diseases. For the treatment of cancer, ACT generally involves the transfer of lymphocytes such as chimeric antigen receptor (CAR) T cells. The use of this type of CAR T cells involves recognizing antigens that CAR T cells on tumor cells can bind to, but tumor heterogeneity can make antigen recognition challenging. Therefore, there remains a ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/705C07K16/28C07K19/00
CPCC07K19/00C07K16/2803C07K16/2863A61K2039/505C07K2317/24C07K2317/622C07K2317/92C07K2319/00C07K2319/03C07K2319/33C07K14/7051C07K14/4748C07K16/32A61P35/00A61P35/02C12N2510/00A61K35/17A61K39/0011A61K2039/5156A61K2039/5158C07K14/70503A61K47/6811A61K47/6851A61K47/6849C07K14/705A61K39/39558A61K2039/572C07K14/70596C07K16/2878C07K16/2887C07K16/30C07K2317/31C07K2317/55C07K2317/56C07K2317/569C07K2317/732C07K2317/734C07K2319/30
Inventor R·罗布P·伦讷特
Owner ALETA BIOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com